Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOF Induction and Post-op Chemoradiotherapy in Esophageal/Gastric Adenocarcinoma
NCT00601705Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2008
- Primary completion
- Mar 2012
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, oxaliplatin, fluorouracil, Cisplatin micelle injection (HA132) in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, Gastric cardia adenocarcinoma (GCA), sponsored by Case Comprehensive Cancer Center. Started Jan 2008; status: completed.
02
Drugs
epirubicinoxaliplatinfluorouracilCisplatin micelle injection (HA132)
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaGastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT00601705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601705.